← Leaderboards
Anas Younes
University Of Tx Md Anderson Can Ctr
$4,435,724
Attributed
$4,435,724
Total exposure
11
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3M · FY2006–19$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$12,100,878 · 13
By mechanism
P50$11,169,460 · 11
R21$931,418 · 2
Top collaborators
- Andrew D. Zelenetz3 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Kapil N. Bhalla$16,921,043
- Hesham M Amin$3,011,396
- Ruitao Lin$859,215
- Xiaodong Cheng$20,199,960
- Varsha Gandhi$2,500,715
Others in their field
Top investigators on “Lymphoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$171,980,034
- Richard L Schilsky · University Of Chicago$120,036,663
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$113,682,224
- Ronald T Mitsuyasu · University Of California Los Angeles$103,553,444
- Monica M Bertagnolli · Strang Cancer Prevention Center$61,393,123
- Charles A Coltman · Southwest Oncology Group$55,198,633
Research focus
LymphomaBaseS LymphomaProgramsClinical TrialsReportingResearch PersonnelEnsureSafetyCollaborationsRelapseTreatment StrategyEnrollmentInhibitor/AntagonistReproduction SporesCell LineMonitorTranslational ResearchHodgkin DiseaseFundingIn VitroCommunicationPathway InteractionsResponse
Grant awards (30)
Development of Mechanism-Based Therapy For Myc+/Bcl2+ Diffuse Large B Cell Lymphoma$267,616
P50 · FY2019 · CA · contact PI
Administrative Core$237,037
P50 · FY2019 · CA · contact PI
DEVELOPMENTAL RESEARCH PROGRAM$216,404
P50 · FY2019 · CA · contact PI
MSK SPORE in Lymphoma$2,251,577
P50 · FY2018 · CA · contact PI
Development of Mechanism-Based Therapy For Myc+/Bcl2+ Diffuse Large B Cell Lymphoma$287,761
P50 · FY2018 · CA · contact PI
Administrative Core$254,877
P50 · FY2018 · CA · contact PI
DEVELOPMENTAL RESEARCH PROGRAM$232,692
P50 · FY2018 · CA · contact PI
MSK SPORE in Lymphoma$2,251,577
P50 · FY2017 · CA · contact PI
Development of Mechanism-Based Therapy For Myc+/Bcl2+ Diffuse Large B Cell Lymphoma$286,355
P50 · FY2017 · CA · contact PI
Administrative Core$256,039
P50 · FY2017 · CA · contact PI
DEVELOPMENTAL RESEARCH PROGRAM$234,682
P50 · FY2017 · CA · contact PI
MSK SPORE in Lymphoma$2,162,000
P50 · FY2016 · CA · contact PI
Development of Mechanism-Based Therapy For Myc+/Bcl2+ Diffuse Large B Cell Lymphoma$275,717
P50 · FY2016 · CA · contact PI
Administrative Core$245,228
P50 · FY2016 · CA · contact PI
DEVELOPMENTAL RESEARCH PROGRAM$224,278
P50 · FY2016 · CA · contact PI
Epigenetic-based therapy of Hodgkin lymphoma$65,809
P50 · FY2011 · CA · contact PI
Administrative Core$45,412
P50 · FY2011 · CA · contact PI
Clinical Research Core$45,386
P50 · FY2011 · CA · contact PI
UT M.D. Anderson Cancer Center Lymphoma SPORE$500,000
P50 · FY2010 · CA · contact PI
Epigenetic-based therapy of Hodgkin lymphoma$69,164
P50 · FY2010 · CA · contact PI
Administrative Core$47,731
P50 · FY2010 · CA · contact PI
Clinical Research Core$47,700
P50 · FY2010 · CA · contact PI
UT M.D. Anderson Cancer Center Lymphoma SPORE$500,000
P50 · FY2009 · CA · contact PI
Clinical Activity of MGCD-0103 in Hodgkin Lymphoma$250,200
R21 · FY2009 · CA · contact PI
Epigenetic-based therapy of Hodgkin lymphoma$69,091
P50 · FY2009 · CA · contact PI
Administrative Core$47,677
P50 · FY2009 · CA · contact PI
Clinical Research Core$47,650
P50 · FY2009 · CA · contact PI
Clinical Activity of MGCD-0103 in Hodgkin Lymphoma$250,200
R21 · FY2008 · CA · contact PI
Clinical Activity of 17-AAG in Lymphoma$212,338
R21 · FY2007 · CA · contact PI
Clinical Activity of 17-AAG in Lymphoma$218,680
R21 · FY2006 · CA · contact PI